Endoscopic Score in CD and UC

  • Salvatore Oliva


Reporting of endoscopic disease activity should always include accurate descriptors of any abnormalities in each segment. The scoring of endoscopic disease activity is becoming an important clinical endpoint in clinical trials as well as in clinical practice. As investigators become more familiar with enrolling children into studies with endoscopic endpoints, such as mucosal healing, validated scoring systems will be essential. Scoring systems used in adults may not be easily extrapolated to children, since the distribution and severity of inflammation noted during pediatric endoscopy may be patchy. A wider application of the scoring system and the development of newer scores will help in management of pediatric IBD patients.


CDEIS SES-CD Mayo endoscopic score UCEIS Mucosal healing 


  1. 1.
    Dulai PS, Levesque BG, Feagan BG, et al. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc. 2015;82:246–55.CrossRefGoogle Scholar
  2. 2.
    Samaan MA, Mosli MH, Sandborn WJ, et al. A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis. 2014;20:1465–71.CrossRefGoogle Scholar
  3. 3.
    Khanna R, Khanna R, Bouguen G, et al. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn’s disease: recommendations for clinical trial design. Inflamm Bowel Dis. 2014;20:1850–61.CrossRefGoogle Scholar
  4. 4.
    Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982–1018.CrossRefGoogle Scholar
  5. 5.
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–9.CrossRefGoogle Scholar
  6. 6.
    Mazzuoli S, Guglielmi FW, Antonelli E, et al. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45:969–77.CrossRefGoogle Scholar
  7. 7.
    Turner D, Griffiths AM, Veerman G, et al. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol. 2013;11:1460–5.CrossRefGoogle Scholar
  8. 8.
    Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61:535–42.CrossRefGoogle Scholar
  9. 9.
    Samuel S, Bruining DH, Loftus EV Jr, et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 2013;11:49–54.CrossRefGoogle Scholar
  10. 10.
    Vuitton L, Peyrin-Biroulet L, Colombel JF, et al. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther. 2017;45:801–13.CrossRefGoogle Scholar
  11. 11.
    Thia KT, Loftus EV Jr, Pardi DS, et al. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011;17:1257–64.CrossRefGoogle Scholar
  12. 12.
    Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983–9.CrossRefGoogle Scholar
  13. 13.
    Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc. 2006;63:433–42.CrossRefGoogle Scholar
  14. 14.
    Sanborn WJ, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;112:512–30.CrossRefGoogle Scholar
  15. 15.
    Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60:505–12.CrossRefGoogle Scholar
  16. 16.
    Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25:665–72.CrossRefGoogle Scholar
  17. 17.
    Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99:956–63.CrossRefGoogle Scholar
  18. 18.
    Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–38.CrossRefGoogle Scholar
  19. 19.
    Dave M, Loftus EV Jr. Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (N Y). 2012;8:29–38.Google Scholar
  20. 20.
    Ruemmele FM, Hyams JS, Otley A, et al. Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut. 2014;64:438–46.CrossRefGoogle Scholar
  21. 21.
    Vuitton L, Marteau P, Sandborn WJ, et al. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut. 2016;65:1447–55.CrossRefGoogle Scholar
  22. 22.
    Ferrante M, et al. Validation of endoscopic activity scores in patients with Crohn’s disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013;145:878–86.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pediatric Gastroenterology and Liver Unit, Department of PediatricsSapienza – University of RomeRomeItaly

Personalised recommendations